Moffitt Partners with top cancer centers to endorse goal of eliminating HPV-related cancers
TAMPA, Fla. – Nearly 80 million Americans – one out of every four people – are infected with human papillomavirus (HPV). And of those millions, more than 31,000 will be diagnosed with an HPV-related cancer this year. Despite those staggering figures and the availability of a vaccine to prevent the infections that cause these cancers, HPV vaccination remains low in the United States.
Moffitt Cancer Center has partnered with 69 other National Cancer Institute (NCI)-designated cancer centers, as well as the American Cancer Society, American Association for Cancer Research, American Society for Clinical Oncology, Association of American Cancer Institutes and America Society of Preventive Oncology, to issue a statement urging for increased HPV vaccination and screening to eliminate HPV-related cancers, starting with cervical cancer. These institutions collectively recognize insufficient vaccination as a public health threat and call upon the nations' physicians, parents and young adults to take advantage of this rare opportunity to eliminate several different types of cancer in men and women.
"We have the opportunity to eliminate multiple HPV-related cancers beginning with cervical cancer. To accomplish this goal, we need to utilize our most important tool – HPV vaccination," said Anna R. Giuliano, Ph.D., director of the Center for Infection Research in Cancer at Moffitt. "We are asking health care providers to stand with us and recommend the HPV vaccine. Parents can join with us by asking their doctors about vaccination."
Vaccination rates remain significantly lower than other recommended adolescent vaccines in the U.S. According 2016 data from the Centers for Disease Control and Prevention (CDC), less than 50 percent of girls and 38 percent of boys completed the recommended vaccine series. Research shows there are a number of barriers to overcome to improve vaccination rates, including a lack of strong recommendations from physicians and parents not understanding that this vaccine protects against several types of cancer in men and women. HPV causes multiple cancers including cervical, anal, oropharyngeal (middle throat) and other genital cancers.
HPV experts from the nation's top cancer centers, along with partners from the NCI, CDC, and the American Cancer Society, are meeting June 7-8 in Salt Lake City to discuss a path forward to eliminating cancers caused by HPV, including ways to reduce barriers to vaccination, as well as share education, training and intervention strategies to improve vaccination rates.
"The United States has an unprecedented opportunity to not just prevent cancers caused by HPV but to eliminate them. This means getting to a point in time when cancers such as cervical cancer are no longer diagnosed in our country," said Giuliano.
This is the third year that all NCI-designated cancer centers have come together to issue a national call to action. All 70 cancer centers unanimously share the goal of sending a powerful message to parents, adolescents and health care providers about the importance of HPV vaccination for the elimination of HPV-related cancers.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 49 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt devotes more than 2 million square feet to research and patient care. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 5,700 team members, Moffitt has an economic impact in the state of $2.1 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube.